Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUMATRIPTAN AND NAPROXEN SODIUM vs PATADAY ONCE DAILY RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.
Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.
Acute treatment of migraine with or without aura in adults,Off-label: Acute treatment of cluster headache (sumatriptan component)
Treatment of ocular itching associated with allergic conjunctivitis (FDA-approved)
Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.
1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).
Sumatriptan: 2.5 hours (range 2-4 hours); Naproxen: 12-17 hours (mean 14 hours). Clinical context: Sumatriptan half-life supports short dosing interval; Naproxen half-life allows twice-daily dosing for migraine prevention.
Terminal elimination half-life is approximately 9 hours; allows twice-daily dosing for sustained symptom control.
Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A) to an indoleacetic acid metabolite. Naproxen sodium is metabolized by hepatic CYP enzymes (CYP1A2, CYP2C9) and other pathways, with glucuronidation.
Olopatadine undergoes minimal hepatic metabolism; approximately 60-70% excreted unchanged in urine. Metabolites include N-demethylated and N-oxide derivatives; CYP450 enzymes not significantly involved.
Sumatriptan: 57% renal (22% unchanged), 38% fecal; Naproxen: 95% renal (mostly as conjugated metabolites, <5% unchanged), <5% fecal.
Primarily renal excretion: approximately 60% of dose excreted unchanged in urine; fecal elimination accounts for less than 10%.
Sumatriptan: 14-21% (primarily albumin); Naproxen: >99% (albumin, extensively bound).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Sumatriptan: 2.4 L/kg (suggests extensive tissue distribution); Naproxen: 0.16 L/kg (confined primarily to plasma and synovial fluid).
Volume of distribution is approximately 1.4 L/kg, indicating distribution into total body water.
Sumatriptan: Oral 15% (due to first-pass metabolism), subcutaneous 96%, intranasal 17%; Naproxen: Oral >95% (nearly complete).
Ocular bioavailability is low due to nasolacrimal drainage and systemic absorption; systemic bioavailability from ocular dose is less than 5%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min); no adjustment recommended for mild to moderate impairment.
No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution as safety has not been established.
Contraindicated in severe hepatic impairment (Child-Pugh class C); not recommended in moderate impairment (Child-Pugh class B); no adjustment for mild (Child-Pugh class A).
No dosage adjustment required for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), use with caution as safety has not been established.
Not recommended for patients under 18 years due to safety and efficacy not established.
For children 2 years of age and older: 1 drop in each affected eye once daily. Safety and efficacy in children under 2 years have not been established.
Not recommended in patients ≥65 years due to increased risk of adverse events; no specific dosing adjustments available.
No specific dosage adjustment required. Use the same dose as for younger adults. Overall, no differences in safety or efficacy were observed between elderly and younger patients.
None
None.
Cardiovascular risk: Serious cardiovascular events including myocardial infarction, stroke, and coronary vasospasm, especially in patients with risk factors.,Gastrointestinal risk: NSAID-induced GI bleeding, ulceration, and perforation, particularly in elderly or those with prior GI history.,Hypertension: Elevation in blood pressure, including hypertensive crisis.,Serotonin syndrome: Risk when combined with other serotonergic drugs (e.g., SSRIs, MAOIs).,Renal toxicity: NSAIDs may impair renal function.,Anaphylaxis/allergic reactions: Immediate medical attention required.,Withdrawal headache: Overuse may lead to medication-overuse headache.
Not for injection; for topical ophthalmic use only.,Do not wear contact lenses if eyes are red; wait at least 10 minutes after instillation before inserting lenses.,Contains benzalkonium chloride which may be absorbed by soft contact lenses.,May cause transient stinging or burning upon instillation.
History of coronary artery disease, myocardial infarction, or ischemic heart disease,Coronary vasospasm (Prinzmetal's angina),Uncontrolled hypertension,Cerebrovascular disease (stroke or transient ischemic attack),Peripheral vascular disease,Hemiplegic or basilar migraine,Severe hepatic impairment,Third trimester of pregnancy,History of GI bleeding or perforation related to NSAID use,Active peptic ulcer disease,Concurrent use of MAO-A inhibitors or within 2 weeks of discontinuation,Hypersensitivity to sumatriptan, naproxen, or aspirin/other NSAIDs (including aspirin triad)
Hypersensitivity to olopatadine or any component of the formulation.
No specific food restrictions, but avoid alcohol due to increased GI bleeding risk. May take with or without food. Food may delay absorption slightly but does not affect efficacy.
No known food interactions. No dietary restrictions required.
Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Naproxen: NSAIDs should be avoided after 30 weeks gestation due to risk of premature closure of ductus arteriosus and oligohydramnios; avoid in first and second trimesters unless clearly needed due to potential association with cardiac defects and miscarriage.
Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic doses. No adequate human studies exist. Risk cannot be ruled out; use only if benefit outweighs potential fetal risk.
Sumatriptan: Excreted in breast milk in low amounts (M/P ratio 4.9); infant dose about 3.5% of maternal weight-adjusted dose; limited data show no adverse effects. Naproxen: Excreted in breast milk (M/P ratio 0.01-0.17); infant dose about 1-2% of maternal dose; use caution in premature infants or with prolonged use due to potential NSAID effects.
Olopatadine is excreted in rat milk at concentrations ~2.4 times higher than maternal plasma. No human data on M/P ratio. Caution advised; consider risk-benefit and monitor infant for anticholinergic effects.
Sumatriptan: No dose adjustment recommended based on pharmacokinetic changes; however, consider lowest effective dose and avoid if possible first trimester. Naproxen: Avoid in pregnancy; if essential, use lowest effective dose for shortest duration. No pharmacokinetic data necessitating dose adjustment, but third trimester use is contraindicated.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on available data. Use at lowest effective dose and shortest duration.
Combination tablet provides dual mechanism: sumatriptan (5-HT1B/1D agonist) and naproxen sodium (NSAID). Onset within 30 minutes. Maximum single dose: sumatriptan 85 mg/naproxen 500 mg. Risk of serotonin syndrome with other serotonergic drugs. Avoid in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or history of GI bleeding. Contraindicated within 24 hours of ergot alkaloids or other triptans. Renal dose adjustment necessary for Cr Cl <30 m L/min. Use lowest effective dose for shortest duration. Assess cardiovascular risk before prescribing. May cause drowsiness or dizziness.
Pataday Once Daily Relief contains olopatadine 0.2%, a mast cell stabilizer and antihistamine. For optimal efficacy, instruct patients to administer one drop in each affected eye once daily. Shake bottle before use. Wait at least 5 minutes before inserting contact lenses due to preservative (benzalkonium chloride). Monitor for transient burning or stinging upon instillation. Not for injection. Patients using additional ophthalmic products should separate by 5 minutes.
Take at the first sign of migraine; do not use to prevent migraines.,Do not exceed one tablet in 24 hours; wait at least 2 hours between doses.,Avoid alcohol, as it may increase risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, aspirin) unless directed.,Seek emergency if chest pain, shortness of breath, sudden severe stomach pain, black/bloody stools, or signs of allergic reaction occur.,Avoid driving or operating machinery if drowsy or dizzy.,Notify doctor if you have heart disease, high blood pressure, liver/kidney disease, or are pregnant/nursing.
Do not touch dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait 10 minutes before reinserting.,May cause temporary blurred vision; avoid driving until vision clears.,If you miss a dose, use it as soon as remembered, but skip if near next dose.,Keep bottle tightly closed when not in use; store at room temperature.
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUMATRIPTAN AND NAPROXEN SODIUM vs PATADAY ONCE DAILY RELIEF, answered by our medical review team.
SUMATRIPTAN AND NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.. PATADAY ONCE DAILY RELIEF is a Ophthalmic Antiallergic Agent that works by Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUMATRIPTAN AND NAPROXEN SODIUM and PATADAY ONCE DAILY RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUMATRIPTAN AND NAPROXEN SODIUM is: Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.. The standard adult dose of PATADAY ONCE DAILY RELIEF is: 1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUMATRIPTAN AND NAPROXEN SODIUM and PATADAY ONCE DAILY RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUMATRIPTAN AND NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Nap. PATADAY ONCE DAILY RELIEF is classified as Category C. Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.